The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up

Mon, 09th Dec 2019 11:23

(Alliance News) - Open Orphan PLC and hVIVO PLC on Monday said they have agreed terms on a reverse takeover, which would value the latter at GBP13.0 million.

Under the terms of the agreement, hVIVO shareholders will receive 2.47 new Open Orphan shares per hVIVO share. The deal values hVIVO shares at 15.56 pence each, a 34% premium to the clinical development services company's closing price of 11.62p on Friday.

hVIVO shares were trading 3.2% higher at 12.00p each in London on Monday morning. Drug consulting firm Open Orphan, also listed in London, was 13% lower at 5.00p each.

As the tie-up is deemed a reverse acquisition, Open Orphan needs the approval of its shareholders at a January 6 general meeting to confirm the deal.

Open Orphan said it expects to issue 205.5 million shares under the terms of the merger, with hVIVO shareholders owning just shy of 45% of the enlarged firm.

Open Orphan said: "Open Orphan and hVIVO are AIM-quoted groups that share a similar vision for the future of European Clinical Research Organisations and an entrepreneurial approach to developing further their business through a focus on operational efficiency, organic growth and targeted acquisitions to expand their geographic and service capabilities.

"The Open Orphan directors and the hVIVO directors believe that the combination of the businesses will result in synergies across the enlarged group with each business providing complementary services with limited overlap in existing capabilities and customers."

hVIVO's directors, which have backed the offer, hold a 0.3% stake in the company. Open Orphan shareholders, with an interest totalling roughly 30% of the firm, have also supported the tie-up.

Open Orphan Chief Executive Cathal Friel said: "The merger of Open Orphan and hVIVO is a key milestone in the execution of our strategy to become a larger-scale specialist pharma services business and in complementary segments where specialist skills and know-how command higher margins.

"The merger allows the combined business to maximise shareholder value through delivering cost and revenue synergies across the businesses and one that is better positioned to consistently capture greater market share as part of a properly profitable business with losses confined to the past."

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
14 Dec 2020 11:38

Open Orphan upbeat on progress with nasal Covid-19 vaccine

(Sharecast News) - Specialist pharmaceuticals contract research organisation Open Orphan announced on Monday that the first in-human study of the Codagenix intranasal SARS-CoV-2 vaccine candidate for Covid-19 had gained approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).

Read more
24 Nov 2020 16:27

UK EXECUTIVE CHANGE SUMMARY: Ocean Wilson Long-Time Finance Head Exits

UK EXECUTIVE CHANGE SUMMARY: Ocean Wilson Long-Time Finance Head Exits

Read more
19 Nov 2020 21:18

IN BRIEF: Open Orphan To Lead Challenge Agent Development Consortium

IN BRIEF: Open Orphan To Lead Challenge Agent Development Consortium

Read more
5 Nov 2020 16:32

IN BRIEF: Open Orphan Wins GBP2.5 Million Contract For Influenza Study

IN BRIEF: Open Orphan Wins GBP2.5 Million Contract For Influenza Study

Read more
30 Oct 2020 11:30

Open Orphan secures new two-year contract with German client

(Sharecast News) - Pharmaceutical services company Open Orphan announced a new two-year contract with an unnamed tier 1 Germany-based pharmaceutical company on Friday.

Read more
30 Oct 2020 11:07

Open Orphan Inks Two-Year Contract With Tier 1 German Pharma Company

Open Orphan Inks Two-Year Contract With Tier 1 German Pharma Company

Read more
20 Oct 2020 15:59

IN BRIEF: Open Orphan To Develop Covid Study Model For UK Government

IN BRIEF: Open Orphan To Develop Covid Study Model For UK Government

Read more
20 Oct 2020 09:49

Open Orphan to assist UK govt in Covid-19 study

(Sharecast News) - Pharmaceutical services company Open Orphan has signed a contract with the UK Government that will see the firm assist in the development of a Covid-19 human challenge study model to safely speed up the development of an efficacious vaccine.

Read more
16 Oct 2020 15:24

IN BRIEF: Open Orphan In Talks With UK Government Over Corona Study

IN BRIEF: Open Orphan In Talks With UK Government Over Corona Study

Read more
16 Oct 2020 08:57

Open Orphan continues talks over coronavirus challenge study

(Sharecast News) - Open Orphan updated the market on its talks with the UK government and other partners for a coronavirus challenge study in the UK on Friday, confirming that "advanced negotiations" were ongoing.

Read more
30 Sep 2020 18:37

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

Read more
28 Sep 2020 19:34

IN BRIEF: Open Orphan Wins GBP4.3 Million Human Viral Study Contract

IN BRIEF: Open Orphan Wins GBP4.3 Million Human Viral Study Contract

Read more
24 Sep 2020 17:35

UK TRADING UPDATE SUMMARY: Personal Group Lauds Royal Mail Contract

UK TRADING UPDATE SUMMARY: Personal Group Lauds Royal Mail Contract

Read more
22 Sep 2020 19:35

IN BRIEF: Open Orphan Lauds Venn's Clinical Study Support Contract Win

IN BRIEF: Open Orphan Lauds Venn's Clinical Study Support Contract Win

Read more
22 Sep 2020 09:43

Open Orphan subsidiary wins 'important' new contract

(Sharecast News) - Pharmaceutical contract research organisation Open Orphan secured an "important" new contract to support an unnamed European client via its French subsidiary, Venn Life Sciences.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.